Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis

Modern Rheumatology

Volumn 22, Issue 5, 2012, Pages 659-667

  Antonelli, Alessandro ^a   Fallahi, Poupak ^a   Ferrari, Silvia Martina ^a   Sebastiani, Marco ^b   Manfredi, Andreina ^b   Mazzi, Valeria ^a   Fabiani, Silvia ^a   Centanni, Marco ^c   Marchi, Santino ^a   Ferri, Clodoveo ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autoimmune thyroiditis; Cryoglobulinemia; CXCL10; CXCL11; Hepatitis C

Indexed keywords

AMINOTRANSFERASE; AUTOANTIBODY; CRYOGLOBULIN; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; THYROTROPIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTHRITIS; ARTICLE; ASPIRATION NEEDLE; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE DURATION; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; RAYNAUD PHENOMENON; SJOEGREN SYNDROME; SUBCLINICAL HYPOTHYROIDISM; T LYMPHOCYTE; THYROTROPIN BLOOD LEVEL; WEAKNESS;

BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; THYROIDITIS, AUTOIMMUNE;

EID: 84870321280     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0565-x     Document Type: Article

References (37)

1. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998;187:2009-21.
2. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol. 2001;59:707-15.
3. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev. 2008;8:18-23.
4. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, et al. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol. 2008;103:2488-94.
5. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Sebastiani M, et al. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol. 2010;37:91-7.
6. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Franzoni F, et al. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis. 2009;41:42-8.
7. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005;106:1175-82.
8. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology. 2007;45:569-78.
9. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-Associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis. 2009;200:1774-80.
10. Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol. 2009;83:836-46.
11. Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, et al. Thyroid involvement in patients with overt HCVrelated mixed cryoglobulinaemia. QJM. 2004;97:499-506.
12. Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-Alpha therapy. Nat Rev Gastroenterol Hepatol. 2009;6:633-5.
13. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5:26-34.
14. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, et al. High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab. 2004;89:5496-9.
15. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, et al. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol. 2005;152:171-7.
16. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2011;96: 1859-63.
17. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992; 327:1490-5.
18. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991;34:1606-10.
19. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford). 2004;43:238-40.
20. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117:10-3.
21. Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood. 1993;82:3701-4.
22. Zignego AL, Deny P, Feray O, Ponzetto A, Gentilini P, Tiollais P, et al. Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning. Mol Cell Probes. 1990;4:45-51.
23. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology. 2004;39:1220-9.
24. Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology. 2005;332:130-44.
25. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3-Associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48:1440-50.
26. Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, et al. High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-{gamma}. J Rheumatol. 2011;38:1947-52.
27. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alphachemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-Activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94:1803-9.
28. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator- Activated receptor-Alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab. 2010;95:E413-20.
29. Antonelli A, Ferrari SM, Frascerra S, Corrado A, Pupilli C, Bernini G, et al. Peroxisome proliferator-Activated receptor a agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res. 2011;317: 1527-33.
30. Kimura H, Kimura M, Rose NR, Caturegli P. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol. 2004;77:161-7.
31. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg. 2006;93:1226-31.
32. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab. 2007;92:1485-90.
33. Romagnani S. The Th1/Th2 paradigm in disease. New York: R.G. Landes Company, Austin/Springer; 1997.
34. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem. 2001;276:2986-91.
35. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, et al. IP-10 predicts viral response and therapeutic outcome in difficult-To-Treat patients with HCV genotype 1 infection. Hepatology. 2006;44:1617-25.
36. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-Alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194: 895-903.
37. Diago M, Castellano G, Garcia-Samaniego J, Perez C, Fernandez I, Romero M, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006;55:374-9.